

<?xml version="1.0" encoding="UTF-8"?>
<codeBook version="1.2.2" ID="NMIMR_LYMPHATIC_FILARIASIS_2018" xml-lang="en" xmlns="http://www.icpsr.umich.edu/DDI" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.icpsr.umich.edu/DDI http://www.icpsr.umich.edu/DDI/Version1-2-2.xsd">
<docDscr>
  <citation>
    <titlStmt>
      <IDNo></IDNo>
    </titlStmt>
    <prodStmt>
      <producer></producer>
      <prodDate date="">
        <_value></_value>
      </prodDate>
      <software version="v5">NADA</software>
    </prodStmt>
    <verStmt>
      <version></version>
    </verStmt>
  </citation>
</docDscr>
<stdyDscr>
  <citation>
    <titlStmt>
      <titl>Low Microfilaremia Levels in Three Districts in Coastal Ghana with at Least 16 Years of Mass Drug Administration and Persistent Transmission of Lymphatic Filariasis</titl>
      <subTitl/>
      <altTitl/>
      <parTitl/>
      <IDNo>NMIMR_LYMPHATIC_FILARIASIS_2018</IDNo>
    </titlStmt>
    <rspStmt>
      <AuthEnty affiliation="Department of Parasitology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Legon-Accra, Ghana">Dziedzom K. de Souza</AuthEnty>
      <othId role="Support towards the study" affiliation="Government " email="">
        <p>Regional and district health management teams</p>
      </othId>
      <othId role="Implementation of the study" affiliation="Government" email="">
        <p>NTDP</p>
      </othId>
    </rspStmt>
    <prodStmt>
      <copyright>Noguchi Memorial Institute for Medical Research</copyright>
      <software version="5.0" date="2023-09-15">NADA</software>
      <fundAg abbr="" role="The design of the study, in the collection, analysis and interpretation of the data, or in the publication of the study results.">EDCTP2 programme supported by the European Union</fundAg>
      <grantNo/>
    </prodStmt>
    <distStmt>
      <contact affiliation="Department of Parasitology, Noguchi Memorial Institute for Medical Research,  University of Ghana, Legon-Accra, Ghana" URI="" email="DdeSouza@noguchi.ug.edu.gh">Dziedzom K. de Souza</contact>
      <depDate date=""/>
      <distDate date=""/>
    </distStmt>
    <serStmt>
      <serName/>
      <serInfo/>
    </serStmt>
    <verStmt>
      <version date="">v1</version>
      <verResp/>
      <notes/>
    </verStmt>
    <biblCit format=""/>
    <notes/>
  </citation>
  <stdyInfo>
    <studyBudget/>
    <subject>
                  
                  
    </subject>
    <abstract/>
    <sumDscr>
      <collDate date="2001" event="start" cycle=""/>
      <collDate date="2002" event="end" cycle=""/>
      <nation abbr="GH">Ghana</nation>
      <geogCover>18 LF endemic villages in the AhantaWest, Nzema East and Ellembele Districts in the Western Region of Ghana</geogCover>
      <geogUnit/>
      <anlyUnit/>
      <universe/>
      <dataKind>sample survey data[ssd]</dataKind>
    </sumDscr>
    <!-- qualityStatement - ddi2.5 - complex type
     
     This structure consists of two parts, standardsCompliance and otherQualityStatements. 
     In standardsCompliance list all specific standards complied with during the execution of this 
     study. Note the standard name and producer and how the study complied with the standard. 
     Enter any additional quality statements in otherQualityStatements.
     
     -->
    <qualityStatement>
      <standardsCompliance>
        <standard>
          <standardName/>
          <producer/>
        </standard>
        <complianceDescription/>
      </standardsCompliance>
      <otherQualityStatement/>
    </qualityStatement>
    <notes>Ghana has been implementing mass drug administration (MDA) of ivermectin and
albendazole for the elimination of lymphatic filariasis (LF) since the year 2000, as part of the Global
Programme to Eliminate Lymphatic Filariasis (GPELF). It was estimated that 5–6 years of treatment
would be sufficient to eliminate the disease. Tremendous progress has been made over the years,
and treatment has stopped in many disease endemic districts. However, despite the successful
implementation of MDA, there are districts with persistent transmission. In this study we assessed
the epidemiology of LF in three adjoining districts that have received at least 16 years of MDA.
The assessments were undertaken one year after the last MDA. 1234 adults and 182 children below
the age of 10 years were assessed. The overall prevalence of circulating filarial antigen in the
study participants was 8.3% (95% CI: 6.9–9.9), with an estimated microfilaria prevalence of 1.2%.
The microfilarial intensity in positive individuals ranged from 1 to 57 microfilariae/mL of blood.
Higher antigen prevalence was detected in males (13.0%; 95% CI: 10.3–16.2) compared to females
(5.5%; 95% CI: 4.1–7.2). The presence of infection was also highest in individuals involved in outdoor
commercial activities, with the risks of infection being four- to five-fold higher among farmers,
fishermen, drivers and artisans, compared to all other occupations. Using bednets or participating in
MDA did not significantly influence the risk of infection. No children below the age of 10 years were
found with infection. Detection of Wb123 antibodies for current infections indicated a prevalence of
14.4% (95% CI: 8.1–23.0) in antigen-positive individuals above 10 years of age. No antibodies were
detected in children 10 years or below. Assessment of infection within the An. gambiae vectors of
LF indicated an infection rate of 0.9% (95% CI: 0.3–2.1) and infectivity rate of 0.5% (95% CI: 0.1–1.6).
These results indicate low-level transmission within the districts, and suggest that it will require
targeted interventions in order to eliminate the infection.
</notes>
    <!-- exPostEvaluation ddi2.5
      Use this section to describe evaluation procedures not address in data evaluation processes. 
      These may include issues such as timing of the study, sequencing issues, cost/budget issues, 
      relevance, instituional or legal arrangments etc. of the study. 
      
      The completionDate attribute holds the date the evaluation was completed. 
      The type attribute is an optional type to identify the type of evaluation with or without 
      the use of a controlled vocabulary.
    -->
    <exPostEvaluation completionDate="" type="">
      <evaluationProcess/>
      <outcomes/>
    </exPostEvaluation>
  </stdyInfo>
  <method>
    <dataColl>
      <timeMeth/>
      <!-- collectorTraining - DDI2.5
        
        Collector Training

        Describes the training provided to data collectors including internviewer training, process testing, 
        compliance with standards etc. This is repeatable for language and to capture different aspects of the 
        training process. The type attribute allows specification of the type of training being described.
        
        -->
      <collectorTraining type=""/>
      <frequenc/>
      <sampProc>Study sites were selected following a review of the Neglected Tropical Disease Programme
(NTDP) sentinel and spot check site monitoring data, as well as recommendation from the District
Health Management Team (DHMT). The sample size determination took into consideration the null
hypothesis that an additional MDA is not more effective than the standard single dose per annum
treatment, and the alternate hypothesis that an additional MDA is more effective than the standard
single dose. With prevalence between sites ranging from 1% to 18%, the sample size was determined
assuming an effect size of 0.4, power of 0.80, 37% non-response rate (determined from a previous
study). Thus, 80 participants were targeted from each community, with a total of 1440 participants for
the entire study.</sampProc>
      <sampleFrame>
        <sampleFrameName/>
        <custodian/>
        <universe/>
        <frameUnit isPrimary="">
          <unitType numberOfUnits=""/>
        </frameUnit>
        <updateProcedure/>
      </sampleFrame>
      <deviat/>
      <collMode>A computer-assisted personal interviewing (CAPI) </collMode>
      <collMode/>
      <resInstru/>
      <!-- instrumentDevelopment - DDI2.5             
        Describe any development work on the data collection instrument. Type attribute allows for the optional use of a defined development type with or without use of a controlled vocabulary.
        -->
      <instrumentDevelopment type=""/>
      <collSitu>A computer-assisted personal interviewing (CAPI) using Census and Survey Processing System
(CSPro) was employed to obtain data on age, sex, occupation, place of residence, use of treated bednet,
and participation in MDA.</collSitu>
      <actMin/>
      <ConOps/>
      <weight/>
      <cleanOps/>
    </dataColl>
    <notes/>
    <anlyInfo>
      <respRate/>
      <EstSmpErr/>
      <dataAppr/>
    </anlyInfo>
    <stdyClas/>
    <dataProcessing type=""/>
    <codingInstructions relatedProcesses="" type="">
      <txt/>
      <command formalLanguage=""/>
    </codingInstructions>
  </method>
  <dataAccs>
    <setAvail>
      <accsPlac URI=""/>
      <origArch/>
      <avlStatus/>
      <collSize/>
      <complete/>
      <fileQnty/>
      <notes/>
    </setAvail>
    <useStmt>
      <restrctn/>
      <contact affiliation="Department of Parasitology, Noguchi Memorial Institute for Medical Research,  University of Ghana, Legon-Accra, Ghana" URI="https://noguchi.ug.edu.gh/research-departments/parasitology/" email="DdeSouza@noguchi.ug.edu.gh">Dziedzom K. de Souza</contact>
      <citReq/>
      <deposReq/>
      <conditions/>
      <disclaimer/>
    </useStmt>
    <notes/>
  </dataAccs>
  <notes/>
</stdyDscr>
<dataDscr>
</dataDscr></codeBook